<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642238</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-0732</org_study_id>
    <secondary_id>ISSBRIL0067</secondary_id>
    <nct_id>NCT01642238</nct_id>
  </id_info>
  <brief_title>Antithrombotic Effects of Ticagrelor Versus Clopidogrel</brief_title>
  <official_title>Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin When Administered With Bivalirudin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan J Badimon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and
      bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and
      bivalirudin).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HORIZONS-AMI Trial compared the effectiveness of heparin plus a glycoprotein IIb/IIIa
      inhibitor (GPI) versus bivalirudin in acute myocardial infarction (AMI) patients undergoing
      stent deployment 1. Overall the data showed benefits associated with the bivalirudin
      treatment with lower rates of all-cause mortality, cardiac mortality, re-infarction and
      non-CABG related major bleeding; However, the data seems to indicate a non-significant
      increase in acute stent thrombosis in the bivalirudin group. This observation seems to
      suggest the potential benefits of adding an antiplatelet agent to bivalirudin. A study by
      Dangas G et al found that in the HORIZONS-AMI patients, the group receiving 600 mg
      loading-dose of clopidogrel had significantly lower 30-day unadjusted rates of mortality,
      reinfarction and stent thrombosis than the 300 mg loading-dose group, without increase in
      bleeding rate. Furthermore, even though the benefits of bivalirudin were independent of the
      clopidogrel loading dose; the 600mg LD was associated with more benefits with both
      anticoagulation regimens. Similar observations have been reported in the ARMYDA-6 MI study.

      It is our hypothesis that using ticagrelor instead of clopidogrel, given its more potent and
      faster activity, would have greater antithrombotic activity and therefore may reduce the rate
      of acute stent thrombosis when administered in combination with bivalirudin + ASA in AMI
      patients. To investigate this hypothesis, we will compare the antithrombotic effects of
      ticagrelor with clopidogrel, when administered in combination with ASA and bivalirudin, in
      healthy human volunteers using a cross-over study design. The antithrombotic activity will be
      assessed pre-treatment and 2-hours and 24-hours post treatment, using methodologies including
      Badimon Perfusion chamber, VerifyNow P2Y12 assay, platelet aggregation with Multiplate
      Analyzer and Thromboelastography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet-thrombus Formation in an ex Vivo Model of Thrombosis</measure>
    <time_frame>Pre-treatment baseline and 1 hour</time_frame>
    <description>Change in thrombus size at 1 hour as compared to Pre-treatment baseline, where a positive change represents a decrease in thrombus size.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet-thrombus Formation in an ex Vivo Model of Thrombosis</measure>
    <time_frame>Pre-treatment baseline and 24 hrs post treatment</time_frame>
    <description>Change in thrombus size at 24 hours as compared to Pre-treatment baseline, where a positive change represents a decrease in thrombus size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity</measure>
    <time_frame>Pre-treatment baseline</time_frame>
    <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity</measure>
    <time_frame>1 hr post-treatment</time_frame>
    <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity</measure>
    <time_frame>24-hours post-treatment</time_frame>
    <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Thrombogenicity</measure>
    <time_frame>Pre-treatment baseline</time_frame>
    <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Thrombogenicity</measure>
    <time_frame>1 hr post-treatment</time_frame>
    <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Thrombogenicity</measure>
    <time_frame>24-hours post-treatment</time_frame>
    <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor + ASA + Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel + ASA + Bivalirudin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor + ASA + Bivalirudin</intervention_name>
    <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
    <arm_group_label>Ticagrelor + ASA + Bivalirudin</arm_group_label>
    <other_name>Brilinta (ticagrelor</other_name>
    <other_name>Aspirin (ASA)</other_name>
    <other_name>Angiomax (bivalirudin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel + ASA + Bivalirudin</intervention_name>
    <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
    <arm_group_label>Clopidogrel + ASA + Bivalirudin</arm_group_label>
    <other_name>Plavix (clopidogrel)</other_name>
    <other_name>Aspirin (ASA)</other_name>
    <other_name>Angiomax (bivalirudin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers between 18 and 65 years old.

          -  Body mass index (BMI) 18 - 30 kg/m2 inclusive.

          -  Healthy as assessed by a detailed medical history and physical examination.

          -  Laboratory est results within the normal range.

          -  Ability to provide signed informed consent.

        Exclusion Criteria:

          -  History of clinically relevant disease, bleeding, acute infectious disease or signs of
             acute illness.

          -  Allergy or hypersensitivity to aspirin or thienopyridines, or atopy diagnosed by a
             physician.

          -  Use of medication within one month prior to study drug administration.

          -  History of drug abuse or alcohol consumption &gt;20 g/day.

          -  Inability to abstain from intensive muscular effort or sport competition.

          -  Loss of &gt;400 mL blood or blood donation within 3 months.

          -  Positive serology for hepatitis B (HBs Ag) or hepatitis C.

          -  Conditions associated with hemorrhagic risk.

          -  Positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan J Badimon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zafar MU, Vorchheimer DA, Tewar MP, Giannarelli C, Crippa M, Sartori S, Rodriguez D, Baber U, Mehran R, Badimon JJ. Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thromb Haemost. 2014 Nov;112(5):1069-70. doi: 10.1160/TH14-03-0269. Epub 2014 Aug 7.</citation>
    <PMID>25104302</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <results_first_submitted>August 14, 2014</results_first_submitted>
  <results_first_submitted_qc>June 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Juan J Badimon</investigator_full_name>
    <investigator_title>Director, AtheroThrombosis Research Unit</investigator_title>
  </responsible_party>
  <keyword>Antiplatelet</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>bivalirudin</keyword>
  <keyword>thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>15 healthy volunteers recruited between July 2012 and March 2013</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor, Then Clopidogrel</title>
          <description>Acute antithrombotic effects of ticagrelor (180 mg + 90 mg) versus clopidogrel (600mg), when coadministered with aspirin (81mg) and bivalirudin (weight-adjusted clinical dose, given as bolus plus 1-hour infusion) with a 1-2 week washout period in between.</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel, Then Ticagrelor</title>
          <description>Acute antithrombotic effects of ticagrelor (180 mg + 90 mg) versus clopidogrel (600mg), when coadministered with aspirin (81mg) and bivalirudin (weight-adjusted clinical dose, given as bolus plus 1-hour infusion) with a 1-2 week washout period in between.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1-2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antithrombotic Effects</title>
          <description>Acute antithrombotic effects of ticagrelor (180 mg + 90 mg) versus clopidogrel (600mg), when coadministered with aspirin (81mg) and bivalirudin (weight-adjusted clinical dose, given as bolus plus 1-hour infusion) using a randomized, two-treatment, two-period, cross-over design in healthy volunteers.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" lower_limit="26.8" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" lower_limit="24.9" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet-thrombus Formation in an ex Vivo Model of Thrombosis</title>
        <description>Change in thrombus size at 1 hour as compared to Pre-treatment baseline, where a positive change represents a decrease in thrombus size.</description>
        <time_frame>Pre-treatment baseline and 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet-thrombus Formation in an ex Vivo Model of Thrombosis</title>
          <description>Change in thrombus size at 1 hour as compared to Pre-treatment baseline, where a positive change represents a decrease in thrombus size.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="43.5" upper_limit="69.0"/>
                    <measurement group_id="O2" value="35.2" lower_limit="23.9" upper_limit="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Platelet-thrombus Formation in an ex Vivo Model of Thrombosis</title>
        <description>Change in thrombus size at 24 hours as compared to Pre-treatment baseline, where a positive change represents a decrease in thrombus size.</description>
        <time_frame>Pre-treatment baseline and 24 hrs post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet-thrombus Formation in an ex Vivo Model of Thrombosis</title>
          <description>Change in thrombus size at 24 hours as compared to Pre-treatment baseline, where a positive change represents a decrease in thrombus size.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="24.3" upper_limit="43.9"/>
                    <measurement group_id="O2" value="18.5" lower_limit="4.2" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity</title>
        <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
        <time_frame>Pre-treatment baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity</title>
          <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
          <units>percent inhibition</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0.5" upper_limit="5.3"/>
                    <measurement group_id="O2" value="3.7" lower_limit="0.9" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity</title>
        <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
        <time_frame>1 hr post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity</title>
          <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
          <units>percent inhibition</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="52.9" upper_limit="85.9"/>
                    <measurement group_id="O2" value="20.1" lower_limit="14.5" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity</title>
        <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
        <time_frame>24-hours post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity</title>
          <description>Platelet reactivity measured by VerifyNowP2Y12 assay measuring percent inhibition</description>
          <units>percent inhibition</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" lower_limit="54.7" upper_limit="80.1"/>
                    <measurement group_id="O2" value="53.4" lower_limit="38.7" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Thrombogenicity</title>
        <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
        <time_frame>Pre-treatment baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Thrombogenicity</title>
          <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="48.8" upper_limit="57.5"/>
                    <measurement group_id="O2" value="51.1" lower_limit="45.0" upper_limit="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Thrombogenicity</title>
        <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
        <time_frame>1 hr post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Thrombogenicity</title>
          <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.1" lower_limit="145.8" upper_limit="180.5"/>
                    <measurement group_id="O2" value="174.0" lower_limit="155.5" upper_limit="192.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Thrombogenicity</title>
        <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
        <time_frame>24-hours post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + ASA + Bivalirudin</title>
            <description>Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Ticagrelor + ASA + Bivalirudin: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + ASA + Bivalirudin</title>
            <description>Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Clopidogrel + ASA + Bivalirudin: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Thrombogenicity</title>
          <description>Coagulation times, assessed using the ROTEM thromboelastometry</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" lower_limit="50.8" upper_limit="61.4"/>
                    <measurement group_id="O2" value="54.3" lower_limit="49.6" upper_limit="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>there were no adverse events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor, Then Clopidogrel</title>
          <description>Acute antithrombotic effects of ticagrelor (180 mg + 90 mg) versus clopidogrel (600mg), when coadministered with aspirin (81mg) and bivalirudin (weight-adjusted clinical dose, given as bolus plus 1-hour infusion) with a 1-2 week wash out period in between.</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel, Then Ticagrelor</title>
          <description>Acute antithrombotic effects of ticagrelor (180 mg + 90 mg) versus clopidogrel (600mg), when coadministered with aspirin (81mg) and bivalirudin (weight-adjusted clinical dose, given as bolus plus 1-hour infusion) with a 1-2 week wash out period in between.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juan J. Badimon</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>(212) 241-8484</phone>
      <email>Juan.Badimon@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

